Abstract: The present invention provides a method for the early diagnosis, prognosis and differentiation of ischemic cardiac events in myocardial ischemia by a Nourin gene-based RNA molecular network of biomarkers to: (a) diagnose unstable angina and AMI (STEMI and NSTEMI) patients, and differentiate between unstable angina and AMI; (b) diagnose ACS patients and differentiate them from symptomatic non-cardiac patients and healthy subjects; (c) diagnose angina in suspected patients with history of chest pain and differentiate angina patients from symptomatic non-angina and healthy subjects; and (d) diagnose “new-onset” heart failure and provide a prognostic value and risk prediction of progression and deterioration, as well as monitoring patients' response to treatments. Downregulation of Nourin-related lncR-CTB9H12.

Abstract: The present invention provides a novel mechanism based on a new paradigm involving up-regulation of Nourin protein and its downstream regulatory network discovered in cardiac systems for its high energy demand and targeting such ischemic events and ischemia-induced disease in another high energy and ATP requiring organ system, that of brain and neuro system and discloses a method for prevention and treatment of neuro diseases and neurological surgical procedures using the bioenergetic drugs, Cyclocreatine (CCr) and Cyclocreatine Phosphate (CCrP). Bioenergetic drugs of the present invention are used for their targeting of depletion of ATP, anti-inflammatory, and anti-apoptotic functions against downstream ischemia-induced injury and tissue deterioration events including, inflammation, apoptosis, necrosis, organ failure, and loss of organ function.

Abstract: The present invention provides methods and composition of a novel mechanism using the bioenergetic Cyclocreatine Phosphate as a potent cardioprotective drug by preserving cellular energy source, preventing ischemic injury, rejuvenating organ function, thus, maintaining normal physical activity. Cyclocreatine Phosphate can be used as a new therapeutic approach to prevent disease development and progression, and to treat ischemia-induced diseases in ischemic heart disease patients, including: coronary artery disease, unstable angina, acute myocardial infarction, heart failure, atrial fibrillation, and Takotsubo cardiomyopathy, as well as provides cardioprotection during cardiac procedures and surgeries. The invention further provides methods and composition to prevent and treat aging-related neurodegenerative diseases where hypoxia/ischemia play a key role in the development and progression of the disease.

Abstract: The present invention provides a method for the early diagnosis, prognosis and differentiation of ischemic cardiac events in myocardial ischemia by a Nourin gene-based RNA molecular network of biomarkers to: (a) diagnose unstable angina and AMI (STEMI and NSTEMI) patients, and differentiate between unstable angina and AMI; (b) diagnose ACS patients and differentiate them from symptomatic non-cardiac patients and healthy subjects; (c) diagnose angina in suspected patients with history of chest pain and differentiate angina patients from symptomatic non-angina and healthy subjects; and (d) diagnose “new-onset” heart failure and provide a prognostic value and risk prediction of progression and deterioration, as well as monitoring patients' response to treatments. Downregulation of Nourin-related lncR-CTB9H12.

Abstract: The present invention provides methods and composition of a novel mechanism using the bioenergetic Cyclocreatine Phosphate as a potent cardioprotective drug by preserving cellular energy source, preventing ischemic injury, rejuvenating organ function, thus, maintaining normal physical activity. Cyclocreatine Phosphate can be used as a new therapeutic approach to prevent disease development and progression, and to treat ischemia-induced diseases in ischemic heart disease patients, including: coronary artery disease, unstable angina, acute myocardial infarction, heart failure, atrial fibrillation, and Takotsubo cardiomyopathy, as well as provides cardioprotection during cardiac procedures and surgeries. The invention further provides methods and composition to prevent and treat aging-related neurodegenerative diseases where hypoxia/ischemia play a key role in the development and progression of the disease.

Abstract: The present invention provides antibodies, devices, and immunoassays for detection of ischemic cardiac events (unstable angina and heart attack) in patients experiencing chest pain. The invention allows for rapid determination of the cause of chest pain, and allows for differentiation of chest pain due to ischemic cardiac events and other causes. The invention provides antibodies that specifically bind to the epitope f-MII and the epitope f-MLF.

Abstract: The present invention provides antibodies, devices, and immunoassays for detection of ischemic cardiac events (unstable angina and heart attack) in patients experiencing chest pain. The invention allows for rapid determination of the cause of chest pain, and allows for differentiation of chest pain due to ischemic cardiac events and other causes. The invention provides antibodies that specifically bind to the epitope f-MII and the epitope f-MLF.

Abstract: The present invention provides compositions and methods for identifying, monitoring, and/or treating tissue inflammation caused by diseases or injury. Inflammatory mediators from the Nourin family are provided as diagnostic markers to detect or monitor a disease or injury that results in inflammation. In addition, the Nourin family antagonist, Nourexin-4 is provided as a therapy to treat diseases or injury. Further, cyclocreatine is provided as an inhibitor of Nourin formation, which can be used as a therapy to treat injury and inflammation.

Abstract: Methods and compositions that can treat a variety of tissue injuries and infections are provided. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.

Abstract: This invention discloses methods and compositions that can treat a variety of tissue injuries and infections. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.

Abstract: The present invention provides compositions and methods for identifying, monitoring, and/or treating tissue inflammation caused by diseases or injury. Inflammatory mediators from the Nourin family are provided as diagnostic markers to detect or monitor a disease or injury that results in inflammation. In addition, the Nourin family antagonist, Nourexin-4 is provided as a therapy to treat diseases or injury. Further, cyclocreatine is provided as an inhibitor of Nourin formation, which can be used as a therapy to treat injury and inflammation.

Abstract: Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.

Abstract: An inflammatory peptide can be a marker for cardiac ischemia.

Abstract: Cyclocreatine phosphate can be prepared in large quantities from inexpensive starting materials to afford a stable product.

Abstract: This invention discloses methods and compositions that can treat a variety of tissue injuries and infections. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.

Abstract: Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.

Abstract: Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.

Abstract: An inflammatory peptide can be a marker for cardiac ischemia.

Abstract: An inflammatory peptide can be a marker for cardiac ischemia.

Abstract: Antibodies to a neutrophil chemotactic protein (NOURIN-I) specific to that protein are provided. The antibodies can be used in diagnostic assays and as pharmaceutical agents. The chemotactic protein represents the initial signal that recruits neutrophils to injured tissue and exhibits a molecular weight of approximately 3 KDa and an isoelectric point of pH 7-8.